Kontinuerlig glukosemonitorering af patienter med type 1- og type 2-diabetes i dialysebehandling

Mette Vadstrup; Tobias Bomholt; Kirsten Nørgaard; Ajenthen G Ranjan; Marianne Rix; Thomas Almdal; Therese Adrian; Bo Feldt-Rasmussen; Mads Hornum

Kontinuerlig glukosemonitorering af patienter med type 1- og type 2-diabetes i dialysebehandling

Mette Vadstrup, Tobias Bomholt, Kirsten Nørgaard, Ajenthen G Ranjan, Marianne Rix, Thomas Almdal, Therese Adrian, Bo Feldt-Rasmussen, Mads Hornum

Steno Diabetes Center Copenhagen

Abstract

Studies indicate, that the glycated haemoglobin (HbA1c) level underestimates the mean blood glucose level in patients with Type 1- and Type 2 diabetes on haemodialysis. In patients receiving peritoneal dialysis the validity of HbA1c level is undetermined. Continuous glucose monitoring (CGM) could be an option for patients with diabetes receiving dialysis to assess the mean blood glucose level independently of the HbA1c level. In addition, CGM makes it possible to investigate periodic hypo- and hyperglycaemia and glucose variability. The evidence for the use of CGM in the dialysis population is limited but could represent an improved approach to glycaemic control.

Bidragets oversatte titel	Continuous glucose monitoring of patients with type 1- and type 2 diabetes on haemodialysis
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	182
Udgave nummer	32
Sider (fra-til)	V03200166
ISSN	0041-5782
Status	Udgivet - 3 aug. 2020

Citationsformater

@article{4bafb5fe28b94070abf0f4bf4a35d7b1,

title = "Kontinuerlig glukosemonitorering af patienter med type 1- og type 2-diabetes i dialysebehandling",

abstract = "Studies indicate, that the glycated haemoglobin (HbA1c) level underestimates the mean blood glucose level in patients with Type 1- and Type 2 diabetes on haemodialysis. In patients receiving peritoneal dialysis the validity of HbA1c level is undetermined. Continuous glucose monitoring (CGM) could be an option for patients with diabetes receiving dialysis to assess the mean blood glucose level independently of the HbA1c level. In addition, CGM makes it possible to investigate periodic hypo- and hyperglycaemia and glucose variability. The evidence for the use of CGM in the dialysis population is limited but could represent an improved approach to glycaemic control.",

author = "Mette Vadstrup and Tobias Bomholt and Kirsten N{\o}rgaard and Ranjan, {Ajenthen G} and Marianne Rix and Thomas Almdal and Therese Adrian and Bo Feldt-Rasmussen and Mads Hornum",

year = "2020",

month = aug,

day = "3",

language = "Dansk",

volume = "182",

pages = "V03200166",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "32",

}

TY - JOUR

T1 - Kontinuerlig glukosemonitorering af patienter med type 1- og type 2-diabetes i dialysebehandling

AU - Vadstrup, Mette

AU - Bomholt, Tobias

AU - Nørgaard, Kirsten

AU - Ranjan, Ajenthen G

AU - Rix, Marianne

AU - Almdal, Thomas

AU - Adrian, Therese

AU - Feldt-Rasmussen, Bo

AU - Hornum, Mads

PY - 2020/8/3

Y1 - 2020/8/3

N2 - Studies indicate, that the glycated haemoglobin (HbA1c) level underestimates the mean blood glucose level in patients with Type 1- and Type 2 diabetes on haemodialysis. In patients receiving peritoneal dialysis the validity of HbA1c level is undetermined. Continuous glucose monitoring (CGM) could be an option for patients with diabetes receiving dialysis to assess the mean blood glucose level independently of the HbA1c level. In addition, CGM makes it possible to investigate periodic hypo- and hyperglycaemia and glucose variability. The evidence for the use of CGM in the dialysis population is limited but could represent an improved approach to glycaemic control.

AB - Studies indicate, that the glycated haemoglobin (HbA1c) level underestimates the mean blood glucose level in patients with Type 1- and Type 2 diabetes on haemodialysis. In patients receiving peritoneal dialysis the validity of HbA1c level is undetermined. Continuous glucose monitoring (CGM) could be an option for patients with diabetes receiving dialysis to assess the mean blood glucose level independently of the HbA1c level. In addition, CGM makes it possible to investigate periodic hypo- and hyperglycaemia and glucose variability. The evidence for the use of CGM in the dialysis population is limited but could represent an improved approach to glycaemic control.

M3 - Tidsskriftartikel

C2 - 32800049

SN - 0041-5782

VL - 182

SP - V03200166

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 32

ER -

Kontinuerlig glukosemonitorering af patienter med type 1- og type 2-diabetes i dialysebehandling

Abstract

Fingeraftryk

Citationsformater